References
- 1. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26:447-462. doi:10.2165/00019053-200826060-00001.10.2165/00019053-200826060-00001
- 2. Stewart S, Jenkins A, Buchan S. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-371. doi: 10.1016/s1388-9842(01)00198-2.10.1016/s1388-9842(01)00198-2
- 3. Lesyuk W, Kriza C, Kolominsky-Rabas P, et al. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18:74. doi: 10.1186/s12872-018-0815-3.10.1186/s12872-018-0815-3
- 4. Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4-25. doi: 10.1002/ehf2.12005.10.1002/ehf2.12005
- 5. Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy. 2017;10:63-70. doi: 10.2147/RMHP.S130341.10.2147/RMHP.S130341
- 6. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368-376. doi: 10.1016/j.ijcard.2013.12.028.10.1016/j.ijcard.2013.12.028
- 7. Dunlay SM, Shah ND, Shi Q, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes. 2011;4:68-75. doi: 10.1161/CIRCOUTCOMES.110.957225.10.1161/CIRCOUTCOMES.110.957225
- 8. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.10.1161/01.cir.0000441139.02102.80
- 9. Reed SD, Whellan DJ, Li Y, et al. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes. 2010;3:374-381. doi: 10.1161/CIRCOUTCOMES.109.907287.10.1161/CIRCOUTCOMES.109.907287
- 10. Ranasinghe I, Wang Y, Dharmarajan K, et al. Readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia among young and middle-aged adults: a retrospective observational cohort study. PLoS Med. 2014;11:e1001737. doi: 10.1371/journal.pmed.1001737.10.1371/journal.pmed.1001737
- 11. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45:391-399. doi: 10.1016/j.jacc.2004.10.038.10.1016/j.jacc.2004.10.038
- 12. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121-1127. doi: 10.1161/CIRCULATIONAHA.104.512988.10.1161/CIRCULATIONAHA.104.512988
- 13. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-1446. doi: 10.1093/eurheartj/ehl012.10.1093/eurheartj/ehl012
- 14. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53:323-330. doi: 10.1016/j.jacc.2008.08.074.10.1016/j.jacc.2008.08.074
- 15. Lorenzovici L, Szekely A, Farkas-Raduly S, Jitaru C, Csanadi M. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania. Journal of Cardiovascular Emergencies. 2019;5:131-139. doi: 10.2478/jce-2019-0018.10.2478/jce-2019-0018
- 16. Rusu ERG, Tartau LM, Statescu C, et al. Study of Dynamics of Immunobiochemical Parameters and Pharmacological Interferences in the Metabolic Syndrome. Revista de Chimie. 2018;69:1493-1497.10.37358/RC.18.6.6353